SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma informs about opening of special window

11 Mar 2026 Evaluate

In order to facilitate ease of investing for investors and to secure their rights in the securities purchased by them, Securities and Exchange Board of India, vide its Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, Marksans Pharma has informed that it has extended a special window to facilitate re-lodgment of transfer deeds that were lodged with respect to shares purchased/sold prior to April 1, 2019 but were rejected, returned or not attended to due to deficiencies in transfer documents or other reasons. In connection with the above matter, it has enclosed a public notice for information of shareholders of the Company.

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma Share Price

179.55 -0.95 (-0.53%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×